Form 4: 2seventy bio Director Charles W. Newton Acquires Shares and Options

Director Charles W. Newton reports acquisition of common stock and stock options in 2seventy bio, Inc.

Summary

• On March 20, 2024, Charles W. Newton, a director of 2seventy bio, Inc., acquired 16,600 shares of common stock.
• The acquisition was made at a price of $0.00 per share.
• Following the transaction, Newton directly owns 16,600 shares of common stock.
• Newton also acquired 33,400 stock options with an exercise price of $4.54.
• These options vest ratably over three years, starting March 20, 2025, contingent upon continued service.
• The options expire on March 20, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of shares and options by a director could be interpreted as a slightly positive signal, but the filing itself is primarily informational.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the Reporting Person's continued service, suggesting an ongoing commitment to the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates